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A B S T R A C T
Purpose
Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has
activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating
mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to
anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in
randomized trials.
Patients and Methods
KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections
collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care
(BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed
by KRAS status.
Results
KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS
mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS
group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P  .0001) than in
the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3
weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and
0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival
(HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure,
more grade III treatment-related toxicities occurred in the WT KRAS group. No significant
differences in toxicity were observed between the WT KRAS group and the overall population.
Conclusion
Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS
status should be considered in selecting patients with mCRC as candidates for panitu-
mumab monotherapy.
J Clin Oncol 26:1626-1634. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Epidermal growth factor receptor (EGFR) has been
validated as a therapeutic target in several human
tumors, including colorectal cancer (CRC).1-4 Li-
gand occupancy of the EGFR activates the RAS/
RAF/MAPK, STAT, and PI3K/AKT signaling
pathways, which together modulate cellular prolif-
eration, adhesion, angiogenesis, migration, and
survival.5,6 The anti-EGFR targeted antibodies
cetuximab and panitumumab administered as
monotherapy inCRChave shown response anddis-
ease stabilization rates of approximately 10% and
30%, respectively.2,3 Although EGFR expression is
used for patient selection, clinical experience shows
that the level of EGFR expression as measured by
immunohistochemistry does not predict clini-
cal benefit.2,7-9
KRAS, the human homolog of the Kirsten rat
sarcoma-2 virus oncogene, encodes a small GTP-
binding protein that acts as a self-inactivating signal
transducer by cycling from GDP- to GTP-bound
states in response to stimulation of a cell surface
receptor, includingEGFR.10,11KRAScanharboron-
cogenic mutations that yield a constitutively active
protein.10-13 Such mutations are found in approxi-
mately 30% to 50% of CRC tumors and are com-
mon in other tumor types.12,14-19 Several studies
have indicated that the presence ofmutantKRAS in
lung andCRC tumors correlates with poor progno-
sis,14,17,18,20 and is associatedwith lackof response to
EGFR inhibitors.15,16,19,21,22 These published re-
ports investigating the role of KRAS as a selection
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marker for EGFR inhibitor treatment were based on tumor samples
from uncontrolled studies and included patients treated with anti-
EGFR antibodies alone or in combination with irinotecan. Given the
possible prognostic role of KRAS mutational status, these uncon-
trolled studies could not isolate the relative effect of antibody treat-
ment onoutcomebyKRAS status from theprognostic implications of
KRAS as a marker of poor clinical outcome in CRC.
We assessed the predictive role of KRAS in a phase III, random-
ized trial comparing panitumumab monotherapy with best support-
ive care (BSC) in patients with chemotherapy-refractory metastatic
CRC.3 The primary objective of the biomarker analyses was to deter-
mine whether the effect of panitumumab monotherapy on
progression-free survival (PFS) differed between patients whose tu-
mors contain mutant versus wild-type (WT; ie, nonmutated)KRAS.
PATIENTS AND METHODS
Trial Design and Patient Population
The design of this controlled, panitumumab monotherapy study has
been previously described.3 Briefly, patients with metastatic CRC with EGFR
expression in 1% of tumor cells (assessed by immunohistochemistry) and
documented evidenceof disease progression after failure of fluoropyrimidines
and prespecified exposure to oxaliplatin and irinotecan were randomly as-
signed to panitumumab 6 mg/kg plus BSC every 2 weeks or BSC alone. BSC
patients could receive panitumumab after disease progression. Tumor status
was assessed radiographically every 4 to 8 weeks from week 8 until disease
progression using the Response Evaluation Criteria in Solid Tumors by
blinded central review. The primary end pointwas PFS, defined as the interval
from random assignment to radiologic progression or death. Secondary end
points included objective response rate, overall survival (OS), and safety. All
patients, including those with unassessable or missing assessments, were in-
cluded in the response rate analysis. A best response of stable disease was
determined at or after week 8 from random assignment. At enrollment, pa-
tients provided informed consent for study procedures including research on
archived paraffin-embedded tumor samples (mostly from primary tumor
resection) for identification of predictive biomarkers. The study protocol was
approved by the ethics board at each research center.
Assay to Detect Mutant KRAS
Formalin-fixed, paraffin-embedded tumor sections were deparaffinized
and air dried, and DNA was isolated using proteinase K and a DNeasy mini-
spin column (Qiagen, Valencia, CA). Mutant KRAS was detected using a
validated KRAS mutation kit (DxS Ltd, Manchester, United Kingdom) that
identifies seven somatic mutations located in codons 12 and 13 (Gly12Asp,
Gly12Ala, Gly12Val, Gly12Ser, Gly12Arg, Gly12Cys, and Gly13Asp) using
allele-specific real-time polymerase chain reaction.23-25 A central laboratory
(HistoGeneX,Antwerp,Belgium)validated the assay for analytic anddiagnos-
tic performance, established acceptance criteria, included appropriate quality
controls for each assay, andperformed theKRAS analysis in a blinded fashion.
Statistical Analysis
Theprimaryobjectiveof thebiomarker analyseswas to examinewhether
the relative effect of panitumumab compared with BSC on PFS differed in
patients with tumors bearingmutant versusWTKRAS. Additional objectives
included examining whether panitumumab improved PFS, OS, and response
rate in theWTKRASgroupcomparedwith theBSCgroup. Safetywas assessed
in both KRAS groups. Analyses were limited to patients with known KRAS
status and were categorized by randomized treatment for efficacy and safety.
Adverse events were graded per the National Cancer Institute Common Tox-
icity Criteria version 2.0 with the exception of selected skin toxicities, which
were graded using version 3.0. Statistical analyses were performed at Amgen
Inc. All analyses were prespecified in a statistical analysis plan before KRAS
mutation assessment.
A quantitative-interaction test26 at a two-sided 5% level was used to
compare the PFS log-hazard ratio (HR; panitumumab relative to BSC) froma
Coxmodelwith covariates for the randomization factors between theWTand
mutant KRAS groups. Based on an assessable sample size of 380 patients and
assuming 60%WT prevalence, power was estimated at more than 99% if the
HR was 1.0 in the mutant KRAS group and at 87% if the HR was 0.80 in the
mutant KRAS group, assuming an overall HR of 0.54 among all patients.
Kaplan-Meier methods were used to estimate PFS and OS. Conditional on a
significant interaction test, sequential testing at a 5% level of PFS, followed by
OS and overall response rate, were planned within the WT KRAS group
between panitumumab versus BSC. A log-rank test was used for PFS, Wil-
coxon for OS, and a generalized Cochran-Mantel-Haenszel test for response
rate, each stratified by the randomization factors.
Maximumchange in tumorburdenper blinded central radiology review
was summarizedby treatment in eachKRAS group. Propensity-score sensitiv-
ity analyses were performed to assess bias due to exclusion of patients with
unknownKRAS status.
RESULTS
Patients
Of the463patients originally enrolled,3 427 (92%)were included
in the KRAS analyses (208 and 219 in the panitumumab and BSC
arms, respectively; Fig 1).KRAS status could not be determined in 18
patients because of unavailable samples and in an additional 18 pa-
tients whose samples had insufficient or poor-quality DNA. KRAS
mutationswere identified in 184 (43%)of 427 patients (84 [40%] and
100 [46%] in the panitumumab and BSC arms, respectively). In the
BSC arm, 76% of patients with WT KRAS and 77% of patients with
mutantKRAS received panitumumab in a cross-over protocol, after a
median PFS time in the original study (investigator assessment) of 7.1
weeks (95% CI, 7.0 to 7.6) and 6.3 weeks (95% CI, 5.1 to 7.1) for
patients in theWT andmutantKRAS groups, respectively.
Baseline patient characteristics were balanced between the WT
andmutantKRAS groups for both panitumumab and BSC (Table 1).
The distribution of specific KRAS mutations was similar between
treatment arms (Table 2).
Efficacy
Primary end point: PFS. Similar to previously described results
in the intent-to-treat population,3 a statistically significant improve-
ment in PFS was observed in the KRAS assessable group between
panitumumab andBSC (HR, 0.59; 95%CI, 0.48 to 0.72).MedianPFS
time was 8.0 weeks for panitumumab and 7.3 weeks for BSC. The
relative effect of panitumumab versus BSC on PFS was significantly
greater among patients with WT KRAS (HR, 0.45; 95% CI, 0.34 to
0.59;medianPFSof12.3weeks forpanitumumabv7.3weeks forBSC)
compared with patients with mutant KRAS, in whom no panitu-
mumabbenefitwas observed (HR, 0.99; 95%CI, 0.73 to 1.36;median
PFS of 7.4 weeks for panitumumab v 7.3 weeks for BSC; Fig 2). The
quantitative-interaction test comparing the magnitude of the relative
treatment effect on PFS between WT and mutant KRAS groups was
statistically significant (P .0001). Consistent results were obtained
with propensity-score adjusted HRs. PFS was significantly greater for
panitumumab versus BSC in theWTKRAS group (stratified log-rank
test P .0001; Fig 2). In all sensitivity analyses performed in theWT
KRAS subset, PFS favored the panitumumab arm. In particular, to
compensate for potential tumor-ascertainment bias in favor of the
BSC arm, an interval-censored sensitivity analysis was performed
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whereby radiologic event times were moved to the closest assessment
time prespecified in the protocol. These analyses showed HR 0.44
(95% CI, 0.30 to 0.63) and median PFS times of 16 and 8 weeks for
panitumumab andBSC, respectively. Across all subsets examined, the
treatment effect of panitumumab on PFS in theWTKRAS groupwas
consistent with the primary analysis (Fig 3). Of 168 BSC patients
receiving panitumumab after progression, PFS was significantly
longer among patients with WT versus patients with mutant KRAS
(HR, 0.32; 95% CI, 0.22 to 0.45; median PFS time of 16.4 weeks for
WT and 7.9 weeks for mutant; online-only Fig A1A).
Response rate. Best overall response data were unassessable or
missing for 35 of 231 patients receiving panitumumab and for 53 of
232 BSC patients (this included 16 of 124 patients receiving panitu-
mumabwithWTKRAS, 16 of 119BSCpatientswithWTKRAS, 15 of
84 patients receiving panitumumab in the mutant KRAS group, and
32 of 100 BSC patients in the mutant KRAS group). In the KRAS
assessable group, response rate for panitumumab was 10%, stable
disease was 25%, and disease progression was 50%. ForKRAS assess-
able patients in the BSC arm, 0% had a response, 10% had stable
disease, and 68% had disease progression. No responders were iden-
tified in the panitumumab mutant KRAS group (100% positive pre-
dictive value for nonresponse in themutant group). In contrast, in the
panitumumab WT KRAS group 21 of 124 patients had a partial
response (17%; 95%CI, 11% to 25%; Fig 4).Median time to response
was 7.9 weeks (range, 7.0 to 15.6 weeks), and median duration of
response was 19.7 weeks (range, 7.9 to 88.7 weeks).
In the WT KRAS group, 42 patients receiving panitumumab
(34%) and 14 BSC patients (12%) had stable disease (Fig 4). In the
mutant KRAS group, stable disease was observed in 10 (12%) and
eight patients (8%) in the panitumumab and BSC arms, respectively.
Consistent results with PFS and response were observed when exam-
ining themagnitude of effect on target lesions for individual patients.
For the WT KRAS group, 61% of patients receiving panitumumab
withavailable target lesionmeasurements (62of101 in theWTgroup)
had a target lesion decrease, including the majority of patients with
stable disease (Fig 4). In contrast, in themutantKRAS group, only 5%
of patients receiving panitumumab (three of 62) had minor tumor
reductions. For the BSCpatients in bothKRAS groups, 3%of patients
(six of 178) had some degree of tumor reduction.
Of 168 BSC patients in the KRAS assessable group that crossed
over to receive panitumumabonprogression, 20 (12%) experienced a
response (including one patient with a complete response), and 55
(33%)had stabledisease.All respondershadWTKRAS, for a response
rate of 20 of 91 (22%; 95%CI, 14% to 32%).
OS. At the time of these analyses, a total of 391KRAS assessable
patients (92%) had died (186 [89%] patients receiving panitumumab
and 205 [94%] BSC patients). Median follow-up time was 14.1
months for the remaining 36 patients. No statistically significant OS
difference was observed between treatment arms among all patients
(HR, 0.97; 95%CI, 0.79 to 1.18), or in either of theKRAS groups; the
HR for OS was 1.02 (95%CI, 0.75 to 1.39) and 0.99 (95%CI, 0.75 to
1.29) for the mutant and WT KRAS groups, respectively. OS was
longer overall in the WT group than in the mutant group adjusting
for stratification factors and randomized treatment (HR, 0.67; 95%
CI, 0.55 to 0.82; both arms combined; Fig 5). Multivariate analysis
showed that WT KRAS status was a predictor for OS in both the
Randomly assigned
(n = 463)
Screened for eligibility
(N = 1,040)
Excluded (did not meet 
inclusion criteria, n = 577)
Randomly assigned to
BSC alone
(n = 232)
Randomly assigned to
panitumumab + BSC
(n = 231)
Excluded from 
KRAS analyses
(missing or unassessable 
samples, n = 36)
Identified as 
mutant KRAS 
(n = 84)
Identified as 
WT KRAS 
(n = 124)
Received panitumumab
under cross-over
protocol 
(n = 77)
Received panitumumab
under cross-over
protocol 
(n = 90)
Identified as 
mutant KRAS 
(n = 100)
Identified as 
WT KRAS 
(n = 119)
Fig 1. CONSORT diagram. BSC, best
supportive care; WT, wild-type.
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panitumumab (HR, 0.64; P  .004) and BSC (HR, 0.68; P  .007)
arms. Similar results for OS were observed among the 168 BSC pa-
tients receiving panitumumab after progression (HR, 0.65; 95% CI,
0.47 to 0.90; median OS time of 6.8 months for WT v 4.5 months
for mutant; online-only Fig A1B). For the 51 BSC patients who did
not cross-over to panitumumab, no difference in OS was observed
betweenWTandmutantKRAS groups (medianOS time of 1.9 and
2 months, respectively).
Exposure and Safety
Themeannumberofpanitumumab infusionswas 10.0 (median,
8.0) and 4.9 (median, 4.0) in WT and mutant KRAS groups, respec-
tively. In themutantKRAS group, 100% of patients receiving panitu-
mumab and 84% of BSC patients had an adverse event. In the WT
KRAS group, these numbers were 100% and 90%, respectively. By
maximumgrade and byKRAS group, a higher incidence of grade 3 or
4 adverse events (44% v 28%) and treatment-related grade 3 adverse
events (25% v 12%) was observed in the panitumumab WT versus
mutant KRAS groups, respectively. In the KRAS assessable popula-
tion, 37%ofpatients had a grade 3or 4 event, and20%ofpatients had
a treatment-related grade 3 or 4 adverse events. The incidence of
adverse events leading to withdrawal in the panitumumab arm was
7%and 5% for theWT andmutantKRAS groups, respectively; 2%of
WT KRAS patients and 1% of mutant KRAS patients withdrew for
panitumumab-related events.
Grade 3 integument-related events occurred in 20% of allKRAS
assessable patients (in 25% of WT KRAS patients and in 13% of
mutant KRAS patients). In the mutant KRAS group, 1% of patients
Table 1. Patient Demographics and Baseline Characteristics by KRAS Status
Characteristic
Mutant Wild-Type
Panitumumab BSC Panitumumab BSC
No. % No. % No. % No. %
No. of patients 84 100 124 119
Sex
Male 47 56 64 64 83 67 76 64
Race/ethnicity
White 84 100 97 97 122 98 118 99
Baseline age, years
Median 62.0 62.0 62.5 63.0
Minimum 27 27 29 32
Maximum 79 83 82 81
Primary diagnosis
Colon cancer 53 63 65 65 86 69 82 69
Rectal cancer 31 37 35 35 38 31 37 31
ECOG performance status
0 43 51 37 37 53 43 40 34
1 28 33 47 47 56 45 62 52
 2* 13 15 16 16 15 12 17 14
Cells with EGFR membrane staining
1% to  10% 20 24 23 23 31 25 29 24
10% to 100% 63 75 77 77 93 75 89 75
Highest membrane staining intensity
3 (strong) 17 20 17 17 25 20 22 18
2 (moderate) 42 50 51 51 69 56 58 49
1 (weak) 24 29 32 32 30 24 39 33
0 1 1 0 0 0 0 0 0
Prior adjuvant chemotherapy
Yes 27 32 40 40 50 40 32 27
Prior lines of chemotherapy
2 54 64 74 74 79 64 63 53
3 23 27 24 24 41 33 49 41
Abbreviations: BSC, best supportive care; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
*Of patients treated with BSC, one patient with wild-type KRAS status and one patient with mutant KRAS status had an ECOG performance status score of 3.
Table 2. Distribution of KRAS Mutations By Treatment Arm
KRAS
Mutation
Total
(N  184)
Panitumumab
(n  84)
BSC
(n  100)
No. % No. % No. %
12Ala 15 8.2 8 9.5 7 7.0
12Asp 70* 38.0 34 40.5 36 36.0
12Arg 3* 1.6 0 0.0 3 3.0
12Val 40 21.7 15 17.9 25 25.0
12Cys 14 7.6 7 8.3 7 7.0
12Ser 14 7.6 5 6.0 9 9.0
13Asp 29 15.8 15 17.9 14 14.0
Abbreviations: BSC, best supportive care; Ala, alanine; Asp, aspartic acid;
Arg, arginine; Val, valine; Cys, cysteine; Ser, serine.
*Two mutations were detected in one specimen.
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had a grade 4 integument-related event; there were no grade 4 events
in the WT group. The time to any integument-related event or to an
event grade 2 or higher was similar in both KRAS groups, suggesting
that incidence differences for integument toxicity were due to differ-
ential exposure. Consistent with previous reports,2,3 patients with the
worst grade skin toxicity in theWT KRAS group appeared to experi-
encebetter PFS andOS (datanot shown). In thepanitumumabarm, a
higher incidence of diarrhea of any grade was observed (WT KRAS
24%; mutant KRAS 19%) but grade 3 diarrhea was comparable be-
tween groups (WT KRAS 2%; mutant KRAS 1%). The incidence of
hypomagnesemia reported as an adverse event of any grade was 3%
and 0% for WT and mutant KRAS groups, respectively. One grade 2
infusion reaction was reported as an adverse event in a patient with
mutantKRAS.
DISCUSSION
These results show that KRAS mutations predict for lack of clinical
benefit topanitumumab therapy.Thepresenceof a control armmade
it possible to study the relative effect of panitumumab monotherapy
by KRAS mutational status independent of the potential prognostic
influence of KRAS mutations on outcomes, enabling us to conclude
that the clinical benefit observed in the KRAS unselected population
was entirely derived from theKRASWTpopulation. Given the cross-
over design, conclusions are limited to the effect of KRAS muta-
tional status on PFS and tumor response end points and not to OS.
Indeed, the majority of BSC patients received panitumumab on
disease progression early in the trial in bothKRAS groups (median
A
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No. of patients at risk
Panit + BSC 84 78 76 72 26 10 8 6 5 5 5 5 4 4 4 4 2 2 2 2 2 2 2 1 1 1
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Fig 2. Progression-free survival by treat-
ment within KRAS groups. Progression-
free survival by randomized treatment in
(A) mutant and (B) wild-type KRAS groups.
Hazard ratios (HR) are shown for panitu-
mumab (panit.) versus best supportive
care (BSC) adjusted for randomization fac-
tors (Eastern Cooperative Oncology Group
score, geographic region).
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time to cross-over was 7.1 weeks), and, importantly, there was demon-
strated benefit of panitumumab after cross-over in patients with WT
KRAS tumors. The difference in OS in favor of theWT KRAS group in
both treatmentarmsobserved inour studymayhavereflectedapotential
prognostic value ofKRASmutational status inCRCor differential sensi-
tivity to panitumumab treatment betweenKRAS groups.
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2
Hazard Ratio (Panit./BSC)
Favors
Panit BSCFactors N HR 95% CI
All randomly assigned 243 0.45 0.34 to 0.59
Male 159 0.42 0.30 to 0.59
Female 84 0.46 0.29 to 0.73
Age: < 65 141 0.42 0.29 to 0.60
Age: 65 + 102 0.47 0.31 to 0.73
Primary: Colon 168 0.47 0.34 to 0.65
Primary: Rectal  75 0.36 0.21 to 0.61
ECOG: 0-1 211 0.47 0.35 to 0.62
ECOG: 2-3 32 0.35 0.15 to 0.82
Prior regimens: 2 142 0.54 0.38 to 0.76
Prior regimens: 3 90 0.28 0.17 to 0.47
Prior regimens: 3+ 100 0.27 0.17 to 0.44
Met. sites: 1-2 172 0.42 0.30 to 0.59
Met. sites: 3-5 69 0.52 0.30 to 0.89
EGFr: 1 to < 10% 60 0.30 0.16 to 0.56
EGFr: 10-35% 101 0.49 0.31 to 0.75
EGFr: > 35% 81 0.34 0.20 to 0.58
EGFr: 1+ 69 0.33 0.18 to 0.63
EGFr: 2+ 127 0.41 0.28 to 0.60
EGFr: 3+ 47 0.37 0.18 to 0.75
Fig 3. Subset analyses of progression-
free survival in the KRAS wild-type group.
Hazard ratio (HR; blue circle) and 95% CI
(horizontal lines) adjusted for randomiza-
tion factors for panitumumab (panit.) ver-
sus best supportive care (BSC). N, sample
size; HR, hazard ratio; ECOG, Eastern Co-
operative Oncology Group; Met, metastat-
ic; EGFr, epidermal growth factor receptor;
1, weak; 2, moderate; 3, strong.
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Fig 4. Waterfall plots showing maximum percent decrease in target lesions (blinded central radiology). (A) Patients receiving panitumumab, mutant KRAS. (B) Patients receiving
panitumumab, wild-type (WT) KRAS. (C) Best supportive care (BSC) patients, mutant KRAS. (D) BSC patients, WT KRAS. Percentages are best response within each KRAS group,
excluding missing or nonassessable postbaseline tumor assessments. PR, partial response (gray); SD, stable disease (yellow); PD, progressive disease (blue).
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Although these analyses were conducted retrospectively, several
aspects relating to the methodology lend robustness to the results.
First, the hypothesis that KRASmutations may confer primary resis-
tance to anti-EGFR antibodies was generated independently from
previous trials. Second, toavoid inflationof type-1error, sampleswere
only subjected to one biomarker analysis, that of KRAS mutation.
Third, the analyses were sufficiently powered and prespecified in a
statistical analysis plan before knowledge of KRAS outcome. Fourth,
testingwas performed by an independent laboratorywithout patient-
level knowledge of randomization or clinical outcomes. Fifth, the
magnitude of the interaction observed is substantial. These consider-
ations, togetherwith consistencywithprevious studies, and the recog-
nized biologic plausibility of the hypothesis, strongly support the
validity of our results and conclusions.
To our knowledge, these are the first results arising from a
randomized, controlled trial showing that the state of a signaling
molecule downstream of a target plays a crucial role in predicting
clinical benefit to a targeted therapeutic. These results also illus-
trate that the presence of a therapeutic target in itself may be
insufficient to predict response to therapy in tumors with multiple
molecular alterations. The high positive predictive value (100% for
lack of objective response rate) for mutant KRAS suggests that
inhibition of the RAS/RAF/MAPK signaling pathway is primarily
responsible for the clinical activity of panitumumab in metastatic
CRC, and raises the possibility that mutant KRAS may be predic-
tive in other tumor types. Indeed, EGFR inhibitors have shown
modest or no activity in pancreatic cancer, a disease with a high
prevalence ofKRASmutations,4,27 and in patients with lung cancer
whose tumors harbor KRASmutations.22,28
In our study, WT KRAS status was shown to be required but
not sufficient to confer sensitivity to panitumumab monotherapy.
Themechanisms of primary and treatment-emergent resistance to
panitumumab in patients with WT KRAS tumors are unknown.
With regard to primary resistance, EGFR may not be a dominant
oncogenic pathway in some tumors, regardless of KRAS status. In
addition, whileKRASmutations occur early in the development of
CRC,29-31 they may also be subsequently acquired, leading to tu-
mor cell heterogeneity. Moreover, while the assay employed in our
study is known to detectmore than 90%of known activatingKRAS
mutations in CRC, it would have missed additional mutations in
codons 12 and 61. Other potential mechanisms of resistance in-
clude activation of additional tyrosine kinase receptors, such as
vascular endothelial growth factor receptor, platelet-derived
growth factor receptor, and insulin-like growth factor 1 receptor7;
activating mutations of additional signaling proteins downstream
of the EGFR, such as PI3K,33 and Src,34 or downstream of KRAS
such as RAF15,35; and loss-of-function mutations of tumor-
suppressor genes such as phosphatase and tensin homolog
(PTEN).33 Elucidating mechanisms of resistance to panitumumab
will prove important for the selection of therapeutic combinations
to maximize clinical benefit. In addition to ascertaining resistance
mechanisms, other biomarkers such as EGFR gene copy number
and expression levels of EGFR ligands in tumor cells may be useful
to further refine the responder population.32,36
The current results apply to the setting of panitumumab
monotherapy and indicate that KRAS status should be considered
when selecting mCRC patients as candidates for this treatment.
Studies are currently underway to assess prospectively whether
KRASmutations also influence response to panitumumab in com-
bination with chemotherapy in earlier lines of therapy. In addition
to the relevance of these results to the current use and to the future
development of anti-EGFR antibodies, these findings may have
implications for the development of oncology therapeutics di-
rected against other targets known to signal though the RAS/RAF/
MAPK pathway.37,38
0
Treatment group    Events  N  % Median (months)
       Panit. wild-type 107 124 86 8.1
       BSC wild-type 110 119 92 7.6
       Panit. mutant 79 84 94 4.9
       BSC mutant 95 100 95 4.4
HR (WT:MT) = 0.67
(95% CI: 0.55 to 0.82)
(Treatment arms combined)
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No. of patients at risk
Panit. wild-type 124 107 92 78 58 41 35 25 18 11 9 8 3 3 2 2 1
BSC wild-type 119 100 82 72 54 41 28 24 18 11 10 9 5 1 1 1 0
Panit. mutant 84 71 51 32 21 16 10 9 6 5 3 3 3 1 1 0 0
BSC mutant 100 84 55 40 30 22 18 11 11 6 3 2 0 0 0 0 0
Fig 5. Kaplan-Meier curves for overall
survival by treatment and KRAS status.
Hazard ratio (HR) for wild-type (WT) versus
mutant (MT) KRAS status adjusted for random-
ized treatment and randomization factors. Pa-
nit, panitumumab; BSC, best supportive care;
events, deaths; N, sample size.
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